Alzheimer's Tau Platform: Regimen A - AADvac1
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age50-80
SponsorPaul S. Aisen
About this trial
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease.
Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.
Eligibility criteria
Qualifiers
No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT06957418).
Disqualifiers
No additional exclusion criteria beyond the exclusion criteria specified in the Master Protocol (NCT06957418).
Trial design
Treatments tested in this trial
- AADvac1
- Donanemab
Treatment groups
450 Participants
are divided into 3 treatment groupsLocations
This trial has no locations
Sponsors and collaborators
Paul S. Aisen
Lead sponsor
University of Southern California
Sponsor institution
Axon Neuroscience SE
Collaborator
University of California, San Francisco
Collaborator
Massachusetts General Hospital
Collaborator
Alzheimer's Therapeutic Research Institute
Collaborator
Alzheimer's Clinical Trials Consortium
Collaborator
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov